Through several rounds of peptide screening and optimisation, we report a 6 amino acid unit containing cyclic peptide (CRVLIR) named cyclo-CRVLIR that is capable of blocking the p110α/RAS interaction in vitro and in several KRAS cancer cell lines. Here, KRAS is linked to cancer.